Top Safest Companies For 2015

Top Safest Companies For 2015: Theravance Inc.(THRX)

Theravance, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. The company?s key development programs with GlaxoSmithKline (GSK) include the RELOVAIR, a Phase 3 clinical trial program for the treatment of patients with chronic obstructive pulmonary disease (COPD) and/or asthma; the LAMA/LABA program, a Phase 3 COPD program; and the Bifunctional Muscarinic Antagonist-beta2 Agonist (MABA) program, a Phase 2b program for the treatment of COPD, as well as Peripherally Selective Mu-Opioid Receptor Antagonist (P Advisors' Opinion:

• [By Roberto Pedone]

  Another biotechnology player that insiders are snapping up a large amount of stock in here is Theravance (THRX), which is a royalty management company, that is focused on developing respiratory products. Insiders are buying this stock into major weakness, since shares have collapsed badly so far in 2014 by 59%.

  Theravance has a market cap of $1.6 billion and an enterprise value of $2 billion. This stock trades at a premium valuation, with a price-to-sales of 578.58. Its estimated growth rate for this year is 17.4%, and for next year it's pegged at 92%. This is not a cash-rich company, since the total cash position on its balance sheet is $310.86 million and its total debt is $705.11 million. This stock currently sports a dividend yield of 3.3%.

  A beneficial owner just bought 832,456 shares, or around $12.78 million worth of stock, at $15.36 per share.

  From a technical perspective, THRX is currently trending well below both its 50-day and 200-day moving averages, which is bearish. This stock has been downtrending badly for the last four months, with shares dropping from its high of $31! .45 to its new 52-week low of $14.50 a share. During that downtrend, shares of THRX have been making mostly lower highs and lower lows, which is bearish technical price action.

  If you're in the bull camp on THRX, then I would look for long-biased trades as long as this stock is trending above its new 52-week low of $14.50 a share and then once it breaks out above some key near-term overhead resistance levels at $16.61 to its 50-day moving average of $17.94 a share and then above more resistance at $18.68 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 824,188 shares. If that breakout triggers soon, then THRX will set up to re-test or possibly take out its next major overhead resistance levels at $21 to $22, or even its 200-day moving average of $23.58 a sh

• [By Sean Williams]

  Things are about to getting very exciting for existing shareholders of biopharmaceutical company Theravance (NASDAQ: THRX  ) , with the company announcing its first-quarter results after the closing bell and setting a record date of May 15 for its split into two separate trading entities.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-safest-companies-for-2015.html